CCL21 and non-small cell lung carcinoma: This has been achieved by using autologous DC to overexpress CCL21, which was the basis of a phase I trial [36] that delivered an injection of autologous DC that overexpressed CCL21 (AdCCL21-DC) in advanced NSCLC.